Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Terapia con vacunas en el tratamiento de pacientes con pólipos de colon avanzados recientemente diagnosticados

17 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Ensayo aleatorizado, doble ciego, controlado con placebo de la vacuna MUC1 en pacientes con adenomas avanzados recién diagnosticados

This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVES:

I. To compare the immunogenicity at week 12 of a MUC1 peptide vaccine with adjuvant (MUC1 peptide-poly-ICLC adjuvant vaccine) (administered at 0, 2, and 10 weeks) in participants with a history of an advanced adenoma, randomized to receive MUC1 peptide vaccine versus placebo.

SECONDARY OBJECTIVES:

I. To evaluate the ability of the vaccine to elicit a long-term memory response.

II. To compare the adenoma recurrence rate from surveillance exams occurring at least 1 year and up to 3 years after week 0 vaccine administration - MUC1 versus placebo.

III. To compare the adenoma recurrence rates between MUC1 and placebo by excluding the following types of adenomas: participants with adenomas =< 5 mm; participants with adenomatous tissue which may represent residual adenoma at the site of the previous advanced adenoma; participants with adenomatous tissue detected in the same segment of the bowel as the previous advanced adenoma.

IV. To assess adverse events to the MUC1 peptide vaccine in comparison to placebo during Parts I and II.

V. To assess patient reported injection site reaction events from the Vaccine Report Card.

TERTIARY OBJECTIVES:

I. To compare the anti-MUC1 antibody titer at the time of surveillance colonoscopy for the purpose of evaluating the anti-MUC1 antibody response in relation to adenoma recurrence.

II. To evaluate MUC1 expression on baseline advanced adenomas and on recurrent adenomas detected at surveillance colonoscopy.

III. To evaluate levels of circulating myeloid derived suppressor cells (MDSC) in the vaccinated and the placebo group and correlate with anti-MUC1 antibody levels and adenoma recurrence.

IV. To establish a biospecimen repository archive including live cells, plasma, and germline deoxyribonucleic acid (DNA) for future immunologic (e.g. MUC1-specific T cells) and other assays (systems biology approach to detect differences between responders and non-responders), testing not currently accommodated within the budget of this trial.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine subcutaneously (SC) in weeks 0, 2 and 10 and a booster injection in week 53.

ARM II: Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.

After completion of treatment, patients are followed up every 6 months for up to 3 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

110

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital Cancer Center
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic in Rochester
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64128
        • Kansas City Veterans Affairs Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Hillman Cancer Center
      • San Juan, Puerto Rico, 00936
        • University of Puerto Rico

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • History of at least one of the following conditions in the previous 12 months:

    • Colorectal adenoma(s) >= 1 cm in maximal diameter
    • Colorectal adenoma(s) with villous or tubulovillous histology
    • Colorectal adenoma(s) with high grade (severe) dysplasia
  • Presumptive evidence that all adenomatous lesions, including qualifying advanced adenoma, have been completely removed

  • Ability to understand and the willingness to sign a written informed consent document

  • Willingness to undergo screening tests and procedures

  • Willingness to provide blood samples for toxicity monitoring and research purposes

  • Not pregnant or nursing; note: a negative (serum or urine) pregnancy test must be documented =< 7 days prior to registration/randomization for women of childbearing potential

  • Willingness to employ adequate contraception through week 53 of the study; note: women of childbearing potential and men must agree to use adequate contraception (hormonal, barrier method of birth control, abstinence) prior to study entry and for the period of active vaccination (through week 53); should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her physician immediately

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • Hemoglobin greater than 90% of the lower limit of institutional normal

  • Platelets >= 100 B/L (10^9/L)

  • White blood cell (WBC) > 2.5 B/L (10^9/L)

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal

  • Alkaline phosphatase =< 1.5 x institutional upper limit of normal

  • Total bilirubin =< 1.5 x institutional upper limit of normal

  • Blood urea nitrogen (BUN) =< 1.5 x institutional upper limit of normal

  • Creatinine =< 1.5 x institutional upper limit of normal

  • Antinuclear antibody (ANA) test result excludes overt autoimmune disease; note: test result may be reported in any of the following formats: =< 1:160, negative, or < 1.0

Exclusion Criteria:

  • History of any colorectal cancer
  • History of other malignancy =< 5 years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer
  • Presence of an active acute or chronic infection or uncontrolled illness including, but not limited to unstable congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Acquired immunosuppressive diseases such as active human immunodeficiency virus (HIV) infection or congenital diseases of immunity
  • History of heritable cancer syndrome (familial adenomatous polyposis [FAP], hereditary nonpolyposis colorectal cancer [HNPCC])
  • History of auto-immune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, Hashimoto's thyroiditis, or Grave's disease
  • Current or planned use of immunomodulators including: infliximab, 6-MP (mercaptopurine), methotrexate, cyclosporine, or other immunomodulatory drugs
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent
  • Pregnant women
  • Breastfeeding women
  • Diagnosis of nonalcoholic steatohepatitis (NASH) and a NAFLD (nonalcoholic fatty liver disease) activity score (NAS) >= 5; NOTES and EXCEPTIONS: NAS is based on findings from a liver biopsy; participants with NAS of =< 2 are eligible for enrollment; participants with NAS of 3-4 must be discussed with the principal investigator and Division of Cancer Prevention (DCP) before enrollment to consider other risk factors (i.e., obesity, alcohol intake); participants with a prior diagnosis of NASH and no available NAS must be discussed with the principal investigator and DCP before enrollment to considered risk factors (i.e., obesity, alcohol intake)
  • Receiving any other investigational agent =< 3 months prior to registration/randomization, except innocuous agents with no known interaction with the study agent (e.g., standard dose multivitamins or topical agents for limited skin conditions)
  • Any use of oral corticosteroids =< 12 weeks prior to registration/randomization

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)

Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.

Correlative studies

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given SC

Comparador de placebos: Arm II (saline)

Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.

Correlative studies

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given SC

Otros nombres:
  • Cloruro de Sodio 0.9%
  • Solución salina normal
  • SOLUCIÓN ISOTÓNICA DE CLORURO DE SODIO

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Anti-MUC1 Immunoglobulin G (IgG) Levels as Determined by Enzyme-linked Immunosorbent Assay (ELISA)
Periodo de tiempo: Week 0 to week 12

The ratio of the week 12 to week 0 IgG levels will be calculated and compared between the MUC1 vaccine and placebo. The Wilcoxon Rank-Sum test will be used. For all measurements of response (i.e. the primary endpoint), the 95% confidence intervals will also be provided.

Week 0 to week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adenoma Recurrence Rate
Periodo de tiempo: At least one year and up to 3 years

The secondary endpoint for Part 3 will evaluate the adenoma recurrence rate from surveillance exams. The rate is defined as the percentage of participants with adenoma recurrence.

At least one year and up to 3 years
Booster Response
Periodo de tiempo: At week 55

The key secondary endpoint for Part 2 will assess the booster response at week 55 vs. week 52 for the vaccine as compared to placebo. The IgG ratios are summarized according to the following categories : <1, 1-<1.5, 1.5-<2, and >=2 (1-year response rate).

At week 55
Participant-reported Injection Site Reactions - Redness at the Injection Site, Swelling/Induration, Itching at Site, and Skin Warmth at Site
Periodo de tiempo: Up to 55 weeks

Participant-reported injection site reaction information is collected by the use of a participant-completed Vaccine Report Card. Participant-reported injection site reactions will be compared between study arms and are summarized below for redness at the injection site, swelling/induration, itching at site, and skin warmth at site.

Up to 55 weeks
Participant-reported Injection Site Reactions - Pain at the Injection Site Without Touching, and Tenderness (Pain at the Injection Site With Touch)
Periodo de tiempo: Up to 55 weeks

Participant-reported injection site reaction information is collected by the use of a participant-completed Vaccine Report Card. Participant-reported injection site reactions will be compared between study arms and are summarized below for pain at the injection site without touching, and tenderness (pain at the injection site with touch).

Up to 55 weeks
Number of Patients With at Least a 2-Fold Increase in the IgG Ratio
Periodo de tiempo: At 12 weeks

The frequency and percentage of patients with at least a 2-fold increase in the IgG Ratio will be calculated and compared between the MUC1 vaccine and placebo. The Fisher's exact test will be used.

At 12 weeks

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Establecimiento de un archivo de depósito de muestras biológicas que incluye células vivas, plasma y ADN de línea germinal para futuros ensayos inmunológicos y de otro tipo
Periodo de tiempo: Hasta 3 años
Hasta 3 años
Incidencia de eventos adversos según la clasificación de los criterios de terminología común para eventos adversos del Instituto Nacional del Cáncer, versión 4.0.
Periodo de tiempo: Hasta 3 años
Hasta 3 años
Anti-MUC1 Antibody Titer by ELISA
Periodo de tiempo: At approximately week 156

Comparisons between MUC1 and placebo will be performed using a two-sample t-test or Wilcoxon rank sum test, as appropriate. All categorical variables will be analyzed using chi-square tests or Fisher's exact test.

At approximately week 156
Change in Levels of Circulating MDSC in Peripheral Blood Mononuclear Cells by Flow Cytometry
Periodo de tiempo: Baseline to up to 3 years

MDSC levels will be correlated with anti-MUC1 antibody levels and adenoma recurrence. Descriptive statistics and simple scatter plots will be generated to review the continuous biomarker data. In addition, for continuous biomarker values, the actual and percent change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each arm using Wilcoxon signed rank tests, and paired sample t-tests.

Baseline to up to 3 years
Change in MUC1 Expression
Periodo de tiempo: Baseline to up to 3 years

Descriptive statistics and simple scatter plots will be generated to review the continuous biomarker data. In addition, for continuous biomarker values, the actual and percent change in the level of each of the biomarkers from baseline to post-baseline time points will be explored within each arm using Wilcoxon signed rank tests, and paired sample t-tests.

Baseline to up to 3 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Robert E Schoen, Mayo Clinic

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

23 de junio de 2014

Finalización primaria (Actual)

27 de enero de 2017

Finalización del estudio (Estimado)

9 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

7 de mayo de 2014

Primero enviado que cumplió con los criterios de control de calidad

7 de mayo de 2014

Publicado por primera vez (Estimado)

9 de mayo de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NCI-2014-01080
  • P30CA015083 (Subvención/contrato del NIH de EE. UU.)
  • N01-CN-2012-00042
  • N01CN00042 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2014-01080 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • HHSN261201200042I
  • MAY2013-01-01 (Otro identificador: DCP)
  • MAY2013-01-01 (Otro identificador: Mayo Clinic in Rochester)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .